Topic
Medical field using vaccines, checkpoint inhibitors, cell therapies, and other immune-boosting treatments to help the body recognize and destroy cancer cells.
More than 80% of high-PD-L1 vesicles from breast cancer cells kept antibodies bound in Kanazawa University imaging. The vesicles came from two cell lines, and the team says the approach needs more research before clinical use.
Reality
Cold Spring Harbor Laboratory researchers activated PPARD in immune cells and saw colorectal tumor growth slow or stop in lab models. The Nature Immunology paper uses CAR T cells, a format already used to treat certain cancers.
Reality
Engineered granulocyte-monocyte progenitors from a USC team slowed blood cancers and solid tumors in mice, according to a study in Cell. A self-renewing source of such cells could ease manufacturing, but every result described so far comes from mice.
Reality
Researchers in Taiwan found 23.5 percent of SSRI users died within two years of starting immunotherapy, against 34.4 percent of matched benzodiazepine users. It is an observational analysis, and the team cannot show the drugs changed anything inside the tumors.
Reality
Memorial Sloan Kettering scientists found that blocking MEK let exhausted cancer-fighting T cells conserve energy and persist near tumors in animal studies. Because MEK inhibitors are already FDA-approved, the lab says the approach could be tested in people soon.
Reality
Merck and Moderna's mRNA vaccine intismeran autogene slowed the return and spread of melanoma when added to an existing treatment in a late-stage trial. One trial cannot say which other cancers the same approach can treat.
Reality
Intismeran autogene met both primary endpoints in a 1,137-patient melanoma trial. Every dose is built from one tumour's sequence, which turns approval into a question about process, not product.
Perspective Coverage
3 publishersReality
Memorial Sloan Kettering researchers used nanoparticles to kill a scar-driving macrophage subset, restoring immunotherapy in mice with liver and lung cancer. The Science paper points to the tumor's fibrotic barrier as a route past immunotherapy resistance.
Reality
The WashU group reports in Nature that the structures activate in mice before distant lymph nodes get the signal, and that a gel of three immune proteins placed under the scalp boosted the antitumor response.
Reality
In Science, a Salk Institute team reports that melanoma cells held in type II interferon spill double-stranded mitochondrial RNA, setting off a type I response that raises COX2 and PGE2, and those cells grew tumors faster in mice.
Reality
Every treated animal cleared its primary tumor in a drug-resistant mouse model. Two of the platform's three arms only fire when a laser reaches the tissue.
Reality
A lipid nanoparticle that carries antigen mRNA, STING mRNA and a delayed-release activator addresses the reason cGAS-STING adjuvants keep failing: the agonist shuts down antigen translation.
Reality